TP-5809

News alerts, weekly reports and conference planners

Company:

Sumitomo Pharma

Drug class:

TNK1 inhibitor

‹

›

almost5years

[VIRTUAL] TP-5809, a novel TNK1 inhibitor, suppresses TNK1 dependent signaling and tumor growth in a preclinical model of Hodgkin’s lymphoma (AACR 2021)

We conclude that TP-5809 is a biologically active TNK1 inhibitor, which could allow further exploration of TNK1 as a clinically relevant therapeutic target in lymphoma and/or other TNK1-dependent cancers. Targeting aberrant TNK1 phosphorylation using TP-5809 can potently and specifically inhibit pathology driven by hyperactive and mutant forms of TNK1.

almost 5 years ago

Preclinical

STAT3 (Signal Transducer And Activator Of Transcription 3)

TP-5809

Unlock More with VERI